In the BioHarmony Drug Report Database

"Preview" Icon

Tretinoin

Altreno, Atralin, Avita, Renova, Retin-a, Retin-a Micro, Retin-a-micro, Vesanoid (tretinoin) is a small molecule pharmaceutical. Tretinoin was first approved as Altreno on 1982-01-01. It is used to treat acne vulgaris, facial dermatoses, hyperpigmentation, and promyelocytic leukemia acute in the USA. The pharmaceutical is active against retinoic acid receptor gamma, retinoic acid receptor alpha, and retinoic acid receptor beta. In addition, it is known to target Nuclear receptor ROR-beta, nuclear receptor subfamily 2 group C member 2, peroxisome proliferator-activated receptor delta, and nuclear receptor subfamily 2 group E member 1. Tretinoin cream’s patent is valid until 2038-08-22 (FDA).

 

Trade Name

 

Altreno, Atralin, Avita, Renova, Retin-a, Retin-a Micro, Retin-a-micro, Vesanoid
 

Common Name

 

tretinoin
 

ChEMBL ID

 

CHEMBL38
 

Indication

 

acne vulgaris, facial dermatoses, hyperpigmentation, promyelocytic leukemia acute
 

Drug Class

 

Retinol derivatives

Image (chem structure or protein)

Tretinoin structure rendering